Fresenius Kabi Sensorcaine-MPF Recall: Subpotent Epinephrine Risk
Fresenius Kabi recalls Sensorcaine-MPF injections with low epinephrine levels that may cause ineffective anesthesia. Patients should contact their doctor for alternatives.
Lower-risk recall
Subpotent Drug: Low out-of-specification assay results for the epinephrine component.
Contact the company
What happened, in plain English
Fresenius Kabi is recalling Sensorcaine-MPF injections that may have lower-than-stated epinephrine levels. This could lead to less effective anesthesia during procedures. Patients should consult their healthcare provider for safer alternatives. Read more at govinfonow.com/recall/36616-fresenius-kabi-sensorcaine-mpf-recall-subpotent-epinephrine-risk.
Source Summary by GovInfoNow · govinfonow.com/recall/36616-fresenius-kabi-sensorcaine-mpf-recall-subpotent-epinephrine-risk · Updated October 4, 2026 · FDA enforcement record: FDA #D-0172-2021
Cite this page
“Fresenius Kabi Sensorcaine-MPF Recall: Subpotent Epinephrine Risk.” GovInfoNow, updated October 4, 2026. https://govinfonow.com/recall/36616-fresenius-kabi-sensorcaine-mpf-recall-subpotent-epinephrine-risk. Based on FDA recall #D-0172-2021 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0172-2021%22&limit=1).
Why it’s dangerous
The injections may contain less epinephrine than labeled, which could result in less effective anesthesia. This might require higher doses of anesthetic or additional procedures to achieve the intended effect.
Who’s affected
Patients using Sensorcaine-MPF injections for anesthesia procedures. Those with specific medical conditions requiring precise epinephrine dosing may be at higher risk.
How to tell if you have this one
Check for the product name Sensorcaine-MPF (Bupivacaine HCl and Epinephrine Injection, USP), 0.5%, 150 mg per 30 mL, 30 mL Single Dose Vial (NDC 63323-462-01). The recall covers batch # 6123760 with expiration date 02/2022.
- Brand
Fresenius Kabi- Category
Drug
What to do — step by step
Contact Your Doctor
Talk to your healthcare provider about alternative anesthesia options since the recalled product may not work as intended.
Where it went and when
Where it was distributed
Distributed nationwide.
FDA distribution: “Nationwide in the USA” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 20 months after the firm started it.
- Firm started the recall
- FDA classified it Class II
- Published in FDA’s Enforcement Report
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Questions people ask
Is this product safe to use?
The recall indicates potential lower epinephrine levels, which could lead to less effective anesthesia. It is not recommended for use without consulting a healthcare provider.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0172-2021 (December 10, 2020) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0172-2021 to see it in context.
- Plain-language summary written by qwen3:4b on October 4, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.